Natco Pharma gets EIR from USFDA for Kothur facility
New Delhi: Drug firm Natco Pharma on Monday said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana. The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company's drug formulations facility in Kothur, Natco Pharma said in a BSE filing.
The plant was inspected from May 30 to June 5, 2019, it added.
Shares of Natco Pharma were trading at Rs 526.75 per scrip on the BSE, down 0.08 percent from its previous close.
Natco Pharma Limited is an Indian pharmaceutical company based in Hyderabad, Telangana, India. Established in 1981 as a private limited company, Natco Pharma develops, manufactures and markets finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's major product categories include Domestic Formulations, International Formulations, APIs and Blockbusters.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here